Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evotec (GB:0IRF)
LSE:0IRF
Evotec (0IRF) Share Price & Analysis
2 Followers
0IRF Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€7.28 - €24.44
Previous Close€8.66
Volume698.54K
Average Volume (3M)219.83K
Market Cap
€1.53B
Enterprise Value€1.70B
Total Cash (Recent Filing)€319.38M
Total Debt (Recent Filing)€506.67M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Aug 14, 2024EPS Estimate
-€0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding177,185,736
10 Day Avg. Volume145,579
30 Day Avg. Volume219,828
Standard Deviation0.13
R-Squared0.06
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)4.45
Price to Sales (P/S)10.22
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.00Price Target Upside73.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Evotec News
Bulls Say, Bears Say
Bulls Say
New Biosimilars DevelopmentSandoz agreed to develop another two biosimilars with Evotec and has agreed to do commercial manufacturing for the entire biosimilar portfolio.
Partnership ExtensionThe recently announced extension of the biosimilar partnership with Sandoz is good news for the case.
Revenue SecurityThis is very good news as it removes a significant element of uncertainty from the case and secures commercial revenues for J.POD 2 for the period after 2030.
Bears Say
Commodity Capacity UtilizationEarnings expectations still reflect low commodity capacity utilization, which is weighing on earnings.
Cyberattack ImpactA cyberattack that occurred provides for a low comparable base and while Q2 earnings expectations look good in a yoy comparison, they still do not compare to Evotec’s EBITDA heydays.
Earnings ForecastExpecting H2 to show an uptick in earnings but modeling a more gradual incline in H2 earnings, prompting a lower FY EBITDA forecast.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.16% Insiders
14.57% Mutual Funds
5.47% Other Institutional Investors
79.81% Public Companies and
Individual Investors
0IRF FAQ
What was Evotec’s price range in the past 12 months?
Evotec lowest share price was €7.28 and its highest was €24.44 in the past 12 months.
What is Evotec’s market cap?
Currently, no data Available
When is Evotec’s upcoming earnings report date?
Evotec’s upcoming earnings report date is Aug 14, 2024 which is in 27 days.
How were Evotec’s earnings last quarter?
Currently, no data Available
Is Evotec overvalued?
According to Wall Street analysts Evotec’s price is currently Undervalued.
Does Evotec pay dividends?
Evotec does not currently pay dividends.
What is Evotec’s EPS estimate?
Evotec’s EPS estimate is -€0.04.
How many shares outstanding does Evotec have?
Evotec has 177,553,390 shares outstanding.
What happened to Evotec’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evotec?
Currently, no hedge funds are holding shares in GB:0IRF
---
Evotec Stock Smart Score
Company Description
Evotec
Evotec SE is a drug discovery partnership company providing drug discovery solutions to pharmaceutical and biotechnology companies, academic institutions as well as foundations and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes and complications of diabetics, pain and inflammation, oncology and infectious diseases. Its business segments are EVT execute and EVT Innovate. The EVT execute provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The majority of the revenue is generated from the EVT execute segment.
---
0IRF Stock 12 Month Forecast
Average Price Target
€15.00
▲(73.29% Upside)
Technical Analysis
Best Analysts Covering 0IRF
1 Year
1 Year Success Rate
6/14 ratings generated profit
1 Year Average Return
-0.33%
reiterated a buy rating 10 days ago
Copying Charles Weston's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -0.33% per trade.
---